NCT04148391 - NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 14, 2019

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions

Mild Cognitive ImpairmentMild DementiaParkinson DiseaseLewy Body Disease

Interventions

DRUG

Placebo Oral Capsule

Matching placebo capsules.

DRUG

NYX-458

NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).

Trial Locations (26)

12601

Aptinyx Clinical Site, Poughkeepsie

28806

Aptinyx Clinical Site, Asheville

30030

Aptinyx Clinical Site, Decatur

32127

Aptinyx Clinical Site, Port Orange

32819

Aptinyx Clinical Site, Orlando

33016

Aptinyx Clinical Site, Miami Lakes

33122

Aptinyx Clinical Site, Miami

33165

Aptinyx Clinical Site, Miami

33173

Aptinyx Clinical Site, Miami

33176

Aptinyx Clinical Site, Miami

33351

Aptinyx Clinical Site, Sunrise

33486

Aptinyx Clinical Site, Boca Raton

33980

Aptinyx Clinical Site, Port Charlotte

34209

Aptinyx Clinical Site, Bradenton

45459

Aptinyx Clinical Site, Dayton

48334

Aptinyx Clinical Site, Farmington Hills

55427

Aptinyx Clinical Site, Golden Valley

74136

Aptinyx Clinical Site, Tulsa

77478

Aptinyx Clinical Site, Sugar Land

78681

Aptinyx Clinical Site, Round Rock

85258

Aptinyx Clinical Site, Scottsdale

93065

Aptinyx Clinical Site, Simi Valley

93710

Aptinyx Clinical Site, Fresno

98007

Aptinyx Clinical Site, Bellevue

99202

Aptinyx Clinical Site, Spokane

08755

Aptinyx Clinical Site, Toms River